BPC-157 guide
This BPC-157 guide sets out what the peptide is, where it stands with regulators, and what the research does and does not show. BPC-157 is unusually easy to find claims about and unusually hard to find good evidence for, so this page cites its sources inline: every number below links to the document it came from.
What BPC-157 is
BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a larger protein reported in gastric juice212. Its sequence is written GEPPPGKPADDAGLV, and FDA gives its molecular weight as about 1,419 g/mol212. It is supplied as a freeze-dried powder that has to be mixed with a sterile diluent before it can be drawn into a syringe.
One practical wrinkle worth knowing: "BPC-157" is a common name rather than an official drug name, there is no pharmacopoeial monograph for it, and the free base and the acetate salt are different substances sold under the same label2. Two vials both labelled BPC-157 are not guaranteed to contain the same thing.
Where BPC-157 stands with regulators
No regulator has approved BPC-157 anywhere in the world, and FDA states there is no approved product containing it in any country2. It is not a prescription medicine that happens to be hard to get; there is no approved labelling for it at all, which is why there is no official indication, dose, contraindication list, or warning section to consult.
In the compounding system, BPC-157 appears on FDA's list of bulk substances that were nominated and then withdrawn by the nominator, having previously sat in category 21. FDA's published position is that compounded drugs containing BPC-157 may pose a risk for immunogenicity by certain routes and may carry complexities around peptide impurities and characterisation of the active ingredient, and that the agency has identified no, or only limited, safety information for the proposed routes, so it lacks sufficient information to know whether the drug would cause harm in humans1.
In 2026 FDA staff reviewed BPC-157 for the 503A bulks list and proposed not adding it. An advisory committee discussed it on 23 July 202623. An official committee outcome was not identified as of September 20, 2026.
For anyone in tested sport, the position is simple: BPC-157 is named in section S0 of the World Anti-Doping Agency's current Prohibited List, the section for substances with no approval for human therapeutic use, and substances in S0 are prohibited at all times, in and out of competition4.
What the research actually shows
Nearly all of it is in animals or in cells. That is not a dismissal, it is a description: the tendon, muscle and gut findings below come from rats, and the mechanism work comes from cell culture and a chick membrane assay.
- Tendon. Rats with a cut Achilles tendon recovered function and tendon strength better when given BPC-15712157, and one study reported improved healing where the tendon attaches to bone13. In cell culture the peptide increased tendon-cell migration and survival, though not cell growth1415.
- Muscle. Rats with a crush injury to the calf, and rats whose muscle-tendon junction had been separated, healed better on functional and tissue measures1817.
- Gut. Rats with chemically induced colitis, and rats with a surgical join in the colon, healed where untreated animals did not16.
- Blood vessels. BPC-157 increased blood-vessel formation and VEGFR2 signalling in animal and laboratory models1415. Even so, FDA's 2026 review states that no molecular target for BPC-157 has been identified and its mechanisms remain poorly understood214.
Two things are worth holding onto while reading any of that. Most published BPC-157 research comes from a single laboratory group: a PubMed search in September 2026 returned 225 records mentioning the compound, and 174 of them list the same senior author1213161718. And when an unconnected group tested it head to head against another peptide in repaired rat tendons, BPC-157 improved histology numerically but did not reach statistical significance on the strength measure, while the comparison peptide did7.
What has been done in people
Less than the internet suggests. There is no completed, published, controlled human efficacy trial of BPC-15756. A randomised, placebo-controlled phase 2 trial in hamstring strain began recruiting in 2026 and has posted no results56.
The only randomised human efficacy result that exists is a 53-participant study of a BPC-157 enema in ulcerative colitis, reported as a conference abstract in 2005 and never published as a full paper. As FDA describes it, the difference between the treated and placebo groups had a confidence interval crossing zero, meaning the study did not show a benefit2.
Beyond that there are three small reports from one clinic: a backwards-looking review of knee injections, a twelve-person single-arm pilot in interstitial cystitis, and a two-person intravenous safety pilot91011. None had a control group or blinding. Reports like these are a reason to run a trial, not a substitute for one.
How long it stays in the body
In rats and dogs, intact BPC-157 clears from the blood in well under 30 minutes, measured at roughly 15 minutes after an intravenous dose in rats, with no intact peptide detectable after four hours8. No human pharmacokinetic data have ever been published, and FDA says as much directly286. Any specific human half-life figure you see quoted has no published basis.
The open safety questions
There is no completed human safety programme, so the honest summary is that the safety profile has not been characterised1. What does exist:
- A 28-day animal toxicity study found altered clotting measures, and in opposite directions in rats and dogs, which has not been replicated. There is no interaction study between BPC-157 and any anticoagulant in people2.
- One rat study found no effect on fetal development at the doses tested, but it did not cover a full reproductive cycle or later development, and there are no human pregnancy data and no lactation data at all2.
- Adverse events reported to FDA in connection with BPC-157 include injection-site reactions, shortness of breath, and darkening of the skin and gums. FDA notes it is unclear whether BPC-157 caused them2.
- The only study to combine BPC-157 with TB-500 found no added benefit over either one alone7. For ipamorelin, CJC-1295, and melanotan II, no interaction data exist at all[unverified].
Storage figures, and where they come from
The storage and shelf-life numbers repeated across peptide sites trace back to peptide suppliers rather than to a published stability programme. FDA reproduces some of those supplier figures while also stating that BPC-157 is not well characterised chemically, that there are no data on impurities or aggregates, and that aggregates can form during storage2. Treat any confident number about how long a reconstituted vial lasts as an estimate without a study behind it.
Reading claims about BPC-157
A useful test on any claim you meet: was it measured in people or in rats, was it measured by a group other than the one that has published most of this literature, and does the source actually say what the page quoting it says. The doses used across the animal studies span a millionfold range with no dose-response relationship established12157, which suggests that even in rats how much to give is not a settled question.
Where the rest of the detail lives
The interactive library on the homepage holds the fuller reference for BPC-157, including commonly referenced dosing ranges, frequency, route, timing, cycle and break information, reconstitution notes, storage, and how compounds are commonly described as interacting. That material is general reference information, the same for every visitor, and the sourcing status of each part of it is set out above. PepCaddie does not sell peptides, does not choose a dose for anyone, and does not replace a clinician who knows your history.
References
These are the sources behind this page, listed so you can read them yourself rather than take our word for it. Animal and laboratory findings do not establish that something works or is safe in people. Doses and protocols shown on a study card are that study's research parameters, not recommendations. PepCaddie does not sell peptides and does not choose a dose for anyone; this is educational material and it does not replace a qualified healthcare professional.
Independent rat tendon study comparing BPC-157 with TB-500
2026Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
A research group unconnected to the laboratory that produced most BPC-157 work repaired transected Achilles tendons in rats and compared BPC-157, TB-500, both together, and no treatment. Both peptides improved histological measures, but only TB-500 reached statistical significance on load to failure. BPC-157 scored numerically better than control without reaching significance on the total histology scores, and combining the two added nothing over either alone.
Limitation: Small groups of eight, a single four-week timepoint, and the authors describe it as exploratory. It is nonetheless the most informative item here, because it is independent and it largely did not find a significant effect.
Randomised controlled animal experiment, four groupsView study: Independent rat tendon study comparing BPC-157 with TB-500
Pharmacokinetics in rats and dogs
2022Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
The first published pharmacokinetic work on BPC-157. Intact peptide left the bloodstream very quickly: an elimination half-life under 30 minutes, measured at about 15 minutes in rats given it intravenously, with no intact drug detectable after four hours. Absorption after intramuscular injection was incomplete, roughly 14 to 19 per cent in rats and 45 to 51 per cent in dogs, and the peptide was broken down into fragments and then amino acids.
Limitation: Animals only. No human pharmacokinetic data exist, and a half-life of minutes sits awkwardly with claims of effects lasting days.
Preclinical pharmacokinetic and ADME studyView study: Pharmacokinetics in rats and dogs
Retrospective review of knee injections
2021Human observational study
A single private clinic looked back at patients who had received BPC-157 injected into the knee and phoned them to ask whether their pain improved. Most reported improvement. The authors describe it as a small study that suggests a possible benefit.
Limitation: This is the weakest design for an efficacy question: looking backwards, no control group, no blinding, and recall over six to twelve months. The authors state no specific tools were used to measure function, quality of life or stiffness.
Retrospective chart review with a telephone follow-up surveyView study: Retrospective review of knee injections
Single-arm pilot in interstitial cystitis
2024Human observational study
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Twelve women whose interstitial cystitis had not responded to standard treatment were given BPC-157 during a single cystoscopy and asked afterwards how they felt. All reported substantial improvement and no adverse events were recorded.
Limitation: No control group, no blinding, twelve patients, one clinic, and a single subjective question as the outcome. A response rate this high in an unblinded pilot is exactly the pattern that later controlled trials often fail to reproduce.
Uncontrolled, unblinded single-arm pilotView study: Single-arm pilot in interstitial cystitis
Two-person intravenous safety pilot
2025Human observational study
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Two adults received intravenous BPC-157 on consecutive days while vital signs and blood markers were monitored. No adverse effects were reported over the three days.
Limitation: Two people, both of whom had taken BPC-157 before and tolerated it, watched for three days. This cannot establish that anything is safe, and the study reports no pharmacokinetic measurements.
Open-label uncontrolled safety pilotView study: Two-person intravenous safety pilot
Rat Achilles tendon transection study
2003Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Rats had the Achilles tendon cut through and were then given BPC-157 or saline. The treated animals scored better on function, on how much load the tendon could take, and on what the tissue looked like under a microscope.
Limitation: An animal model, with no group sizes in the abstract, from the Zagreb laboratory that produced most BPC-157 research. The doses tested span a millionfold range with no dose-response relationship established.
Controlled animal experiment with an in-vitro armView study: Rat Achilles tendon transection study
Rat tendon-to-bone healing study
2006Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Rats had the Achilles tendon detached from the heel bone. Treated animals recovered function and tendon strength better than controls, and BPC-157 offset the worsening of healing caused by a corticosteroid given alongside it.
Limitation: One unreplicated animal study from the dominant research group, with no group sizes in the abstract. The authors suggest it might replace reconstructive surgery, which is far beyond what a rat experiment can support.
Controlled animal experiment with a corticosteroid armView study: Rat tendon-to-bone healing study
Blood-vessel growth and VEGFR2 signalling
2017Animal studyNot human evidence
A group independent of the main BPC-157 laboratory found that the peptide increased blood-vessel formation in a chick membrane assay, improved blood-flow recovery in rats with a restricted hind limb, and raised levels of the VEGFR2 receptor in human endothelial cells grown in the laboratory.
Limitation: A mechanism study, not an outcome study, and it reports an association with a signalling pathway rather than a confirmed molecular target. FDA separately notes that no molecular target for BPC-157 has been identified. The abstract gives no doses.
Mixed animal and laboratory mechanism studyView study: Blood-vessel growth and VEGFR2 signalling
Tendon cell migration in the laboratory
2011Laboratory or in-vitro studyNot human evidence
In cell culture, BPC-157 increased the outgrowth of tendon cells from tissue explants, helped those cells survive chemical stress, and increased their migration, apparently through the FAK-paxillin pathway. Notably, it did not increase cell proliferation.
Limitation: Cells in a dish, not an animal or a person. No concentrations are given in the abstract, and an effect on cell migration does not establish that a tendon heals faster in a living body.
Laboratory experimentView study: Tendon cell migration in the laboratory
Rat colitis and bowel-join healing study
2013Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
In rats with chemically induced colitis and in rats with a surgical join in the colon, animals given BPC-157 healed where untreated animals did not.
Limitation: An animal study from the dominant research group, with no group sizes in the abstract. It bundles unrelated disease models into one paper, which is a pattern worth treating sceptically.
Controlled animal experiment across several injury modelsView study: Rat colitis and bowel-join healing study
Rat muscle-tendon junction study
2021Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Rats had the quadriceps tendon separated from the muscle, an injury the authors describe as one that does not heal on its own. Animals given BPC-157, by injection or in drinking water, showed better recovery on function, biomechanics and tissue measures.
Limitation: An animal study from the dominant research group, with no group sizes in the abstract. Choosing a model defined as unable to heal spontaneously maximises how large any treatment effect looks.
Controlled animal experiment, injected and oral routesView study: Rat muscle-tendon junction study
Rat muscle crush injury study
2010Animal studyNot human evidence
Rats with a crush injury to the calf muscle healed better on function and tissue measures when given BPC-157, including when a corticosteroid that normally impairs healing was given at the same time.
Limitation: An animal study from the dominant research group. The abstract states no dose and no group sizes, and its conclusion that impaired healing was "completely" reversed is a strong absolute claim from scored measures.
Controlled animal experimentView study: Rat muscle crush injury study
Certain bulk drug substances for use in compounding that may present significant safety risks. U.S. Food and Drug Administration; 2026.
Official regulatory sourceChecked 2026-09-20
Read FDA's safety statement on BPC-157 in compounding at the sourcePharmacy Compounding Advisory Committee briefing document: BPC-157 (free base) and BPC-157 acetate. U.S. Food and Drug Administration; 2026.
Official regulatory sourceDocket FDA-2025-N-6895Checked 2026-09-20
Read FDA's 2026 review of BPC-157 for the 503A bulks list at the sourceJuly 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration; 2026.
Official regulatory sourceChecked 2026-09-20
Read FDA advisory committee meeting notice, July 2026 at the sourceThe 2026 Prohibited List, World Anti-Doping Code, valid 1 January 2026. World Anti-Doping Agency; 2026.
Official regulatory sourceChecked 2026-09-20
Read WADA's 2026 Prohibited List at the sourceA randomized, double-blind, placebo-controlled phase 2 trial of pentadecapeptide BPC 157 for accelerated repair of acute grade II hamstring strain confirmed by MRI. ClinicalTrials.gov, sponsor Hudson Biotech; 2026.
Registered clinical trialNCT07437547Checked 2026-09-20
Read Registered phase 2 hamstring trial at the sourcePhase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02, which active ingredient is BPC-157, a penta-deca-peptide from gastric source. ClinicalTrials.gov, sponsor PharmaCotherapia d.o.o.; 2015.
Registered clinical trialNCT02637284Checked 2026-09-20
Read Registered phase 1 safety and pharmacokinetics study at the sourceBiçer O, Adanır O, Güleryüz Y, et al.. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 37(3):822-837; 2026.
Animal studyPMID 42542926 · DOI 10.52312/jdrs.2026.2951Checked 2026-09-20
Read Independent rat tendon study comparing BPC-157 with TB-500 at the sourceHe L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 13:1026182; 2022.
Animal studyPMID 36588717 · DOI 10.3389/fphar.2022.1026182Checked 2026-09-20
Read Pharmacokinetics in rats and dogs at the sourceLee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4):8-13; 2021.
Human observational studyPMID 34324435Checked 2026-09-20
Read Retrospective review of knee injections at the sourceLee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30(10):12-17; 2024.
Human observational studyPMID 39325560Checked 2026-09-20
Read Single-arm pilot in interstitial cystitis at the sourceLee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5):20-24; 2025.
Human observational studyPMID 40131143Checked 2026-09-20
Read Two-person intravenous safety pilot at the sourceStaresinic M, Sebecic B, Patrlj L, et al.. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6):976-983; 2003.
Animal studyPMID 14554208 · DOI 10.1016/S0736-0266(03)00110-4Checked 2026-09-20
Read Rat Achilles tendon transection study at the sourceKrivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 24(5):982-989; 2006.
Animal studyPMID 16583442 · DOI 10.1002/jor.20096Checked 2026-09-20
Read Rat tendon-to-bone healing study at the sourceHsieh MJ, Liu HT, Wang CN, et al.. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3):323-333; 2017.
Animal studyPMID 27847966 · DOI 10.1007/s00109-016-1488-yChecked 2026-09-20
Read Blood-vessel growth and VEGFR2 signalling at the sourceChang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774-780; 2011.
Laboratory or in-vitro studyPMID 21030672 · DOI 10.1152/japplphysiol.00945.2010Checked 2026-09-20
Read Tendon cell migration in the laboratory at the sourceKlicek R, Kolenc D, Suran J, et al.. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of Physiology and Pharmacology, 64(5):597-612; 2013.
Animal studyPMID 24304574Checked 2026-09-20
Read Rat colitis and bowel-join healing study at the sourceJapjec M, Horvat Pavlov K, Petrovic A, et al.. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines, 9(11):1547; 2021.
Animal studyPMID 34829776 · DOI 10.3390/biomedicines9111547Checked 2026-09-20
Read Rat muscle-tendon junction study at the sourcePevec D, Novinscak T, Brcic L, et al.. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor, 16(3):BR81-88; 2010.
Animal studyPMID 20190676Checked 2026-09-20
Read Rat muscle crush injury study at the source